Zuzana Potacova

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: JOURNAL OF IMMUNOTHERAPY. 2017;40(4):132-139
A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer
Omazic B; Ayoglu B; Lohr M; Segersvard R; Verbeke C; Magalhaes I; Potacova Z; Mattsson J; Terman A; Ghazi S; Albiin N; Kartalis N; Nilsson P; Poiret T; Liu Z; Heuchel R; Schwenk JM; Permert J; Maeurer MJ; Ringden O
Article: PLOS ONE. 2017;12(11):e0187294
Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway
El-Serafi I; Terelius Y; Abedi-Valugerdi M; Naughton S; Saghafian M; Moshfegh A; Mattsson J; Potacova Z; Hassan M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2016;22(4):676-681
Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer
Omazic B; Remberger M; Barkholt L; Soderdahl G; Potacova Z; Wersall P; Ericzon B-G; Mattsson J; Ringden O
Article: TOXICOLOGY IN VITRO. 2015;29(7):1711-1719
Copper-based nanoparticles induce high toxicity in leukemic HL60 cells
Rodhe Y; Skoglund S; Wallinder IO; Potacova Z; Moller L
Article: PHARMACOGENOMICS JOURNAL. 2015;15(5):405-413
Cytochrome P450 2J2, a new key enzyme in cyclophosphamide bioactivation and a potential biomarker for hematological malignancies
El-Serafi I; Fares M; Abedi-Valugerdi M; Afsharian P; Moshfegh A; Terelius Y; Potacova Z; Hassan M
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2015;463(3):268-274
DNA damage, lysosomal degradation and Bcl-xL deamidation in doxycycline- and minocycline-induced cell death in the K562 leukemic cell line
Fares M; Abedi-Valugerdi M; Hassan M; Potacova Z
Article: PLOS ONE. 2014;9(12):e114457
Cytotoxic Effects of Tetracycline Analogues (Doxycycline, Minocycline and COL-3) in Acute Myeloid Leukemia HL-60 Cells
Song H; Fares M; Maguire KR; Siden A; Potacova Z
Article: PLOS ONE. 2014;9(1):e86619
Cyclophosphamide Alters the Gene Expression Profile in Patients Treated with High Doses Prior to Stem Cell Transplantation
El-Serafi I; Abedi-Valugerdi M; Potacova Z; Afsharian P; Mattsson J; Moshfegh A; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2013;48(6):843-848
Omega-3 from fish oil augments GVHD through the enhancement of chemotherapy conditioning regimen and selective FoxP3 depletion
Al Hashmi S; Sadeghi B; Hassan Z; Abedi-Valugerdi M; Lindskog M; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2013;48(2):284-293
Early-phase GVHD gene expression profile in target versus non-target tissues: kidney, a possible target?
Sadeghi B; Al-Chaqmaqchi H; Al-Hashmi S; Brodin D; Hassan Z; Abedi-Valugerdi M; Moshfegh A; Hassan M
Article: JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. 2013;913:98-105
Gas chromatographic-mass spectrometry method for the detection of busulphan and its metabolites in plasma and urine
El-Serafi I; Terelius Y; Twelkmeyer B; Hagbjork A-L; Hassan Z; Hassan M
Article: PLOS ONE. 2012;7(1):e30897
Busulphan-Cyclophosphamide Cause Endothelial Injury, Remodeling of Resistance Arteries and Enhanced Expression of Endothelial Nitric Oxide Synthase
Al-Hashmi S; Boels PJM; Zadjali F; Sadeghi B; Sallstrom J; Hultenby K; Hassan Z; Arner A; Hassan M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2011;17(11):1688-1697
Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study
Remberger M; Ackefors M; Berglund S; Blennow O; Dahllof G; Dlugosz A; Garming-Legert K; Gertow J; Gustafsson B; Hassan M; Hassan Z; Hauzenberger D; Hagglund H; Karlsson H; Klingspor L; Kumlien G; Le Blanc K; Ljungman P; Machaczka M; Malmberg K-J; Marschall H-U; Mattsson J; Olsson R; Omazic B; Sairafi D; Schaffer M; Svahn B-M; Svenberg P; Swartling L; Szakos A; Uhlin M; Uzunel M; Watz E; Wernerson A; Wikman A; Wikstrom A-C; Winiarski J; Ringden O
Article: INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY. 2011;4(6):596-605
Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen
Al-Hashmi S; Hassan Z; Sadeghi B; Rozell B; Hassan M
Article: SULTAN QABOOS UNIVERSITY MEDICAL JOURNAL. 2011;11(2):165-178
The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine.
Hassan M; Sallam H; Hassan Z
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2011;41(4):1143-1153
N-acetyl-L-cysteine increases acute graft-versus-host disease and promotes T-cell-mediated immunity in vitro
Karlsson H; Nava S; Remberger M; Hassan Z; Hassan M; Ringden O
Article: TRANSPLANTATION. 2010;90(9):1022-1029
Granulocyte Colony-Stimulating Factor Induced Acute and Chronic Graft-Versus-Host Disease
Ringden O; Hassan Z; Karlsson H; Olsson R; Omazic B; Mattsson J; Remberger M
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2010;84(4):323-331
GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants
Olsson R; Remberger M; Hassan Z; Omazic B; Mattsson J; Ringden O
Article: CLINICAL AND DEVELOPMENTAL IMMUNOLOGY. 2010;2010:142943
Expansion and Activation Kinetics of Immune Cells during Early Phase of GVHD in Mouse Model Based on Chemotherapy Conditioning
Sadeghi B; Al-Hashmi S; Hassan Z; Rozell B; Concha H; Lundmark C; Gronvik K-O; Abedi-Valugerdi M; Hassan M
Article: HLA. 2008;72(6):549-558
Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study
Hauzenberger D; Schaffer M; Ringden O; Hassan Z; Omazic B; Mattsson J; Wikstrom A-C; Remberger M
Article: BONE MARROW TRANSPLANTATION. 2008;42(12):807-818
GVHD after chemotherapy conditioning in allogeneic transplanted mice
Sadeghi B; Aghdami N; Hassan Z; Forouzanfar M; Rozell B; Abedi-Valugerdi M; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2008;41(10):895-904
The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model
Sadeghi B; Jansson M; Hassan Z; Mints M; Hagglund H; Abedi-Valugerdi M; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2008;41(9):785-790
A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation
Barkholt L; Remberger M; Hassan Z; Fransson K; Omazic B; Svahn B-M; Karlsson H; Brune M; Hassan M; Mattsson J; Ringden O
Article: JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES. 2008;31(5):683-694
Rapid and sensitive method for determination of cyclophosphamide in patients plasma samples utilizing microextraction by packed sorbent online with liquid chromatography-tandem mass spectrometry (MEPS-LC-MS/MS)
Said R; Hassan Z; Hassan M; Abdel-Rehim M
Article: BONE MARROW TRANSPLANTATION. 2008;41(4):399-405
Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors -: a single centre study
Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringden O
Article: JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES. 2007;30(20):3029-3041
Simultaneous determination of busulphan in plasma samples by liquid chromatography-electrospray ionization mass spectrometry utilizing microextraction in packed syringe (MEPS) as on-line sample preparation method
Abdel-Rehim M; Hassan Z; Skansem P; Hassan M
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2007;60(6):841-849
Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro
Song H; Vita M; Sallam H; Tehranchi R; Nilsson C; Siden A; Hassan Z
Article: CLINICAL TRANSPLANTATION. 2007;21(5):659-667
Hemorrhagic cystitis:: a retrospective single-center survey
Hassan Z; Remberger M; Svenberg P; Elbander M; Omazic B; Mattsson J; Conrad R; Svahn B-M; Ahlgren A; Sairafi D; Aschan J; Le Blanc K; Barkholt L; Ringden O
Article: CLINICAL CANCER RESEARCH. 2007;13(14):4218-4224
The effect of repeated administration of cyclophosphamide on cytochrome P4502B in rats
Afsharian P; Zuzana YT; Hassan Z; Nilsson C; Lundgren S; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2007;39(7):383-388
Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases
Ringden O; Remberger M; Svenberg P; Svahn B-M; Dahllof G; Gustafsson B; Hassan Z; Omazic B; Uzunel M; Aschan J; Barkholt L; Winiarski J; Ljungman P; Mattsson J
Article: TRANSPLANTATION. 2006;82(7):913-919
Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning
Uzunel M; Remberger M; Sairafi D; Hassan Z; Mattsson J; Omazic B; Barkholt L; Ringden O
Article: TRANSPLANTATION. 2006;81(10):1390-1397
Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease
Ringden O; Uzunel M; Rasmusson I; Remberger M; Sundberg B; Lonnies H; Marschall H-U; Dlugosz A; Szakos A; Hassan Z; Omazic B; Aschan J; Barkholt L; Le Blanc K
Article: TRANSPLANTATION. 2006;81(5):718-725
Allogeneic hematopoietic stem cell transplantation for inherited disorders:: Experience in a single center
Ringdén O; Remberger M; Svahn BM; Barkholt L; Mattsson J; Aschan J; Le Blanc K; Gustafsson B; Hassan Z; Omazic B; Svenberg P; Solders G; von Döbeln U; Winiarski J; Ljungman P; Malm G
Article: EXPERIMENTAL HEMATOLOGY. 2006;34(1):115-121
Myeloablative and immunosuppressive properties of treosulfan in mice
Sjöö F; Hassan Z; Abedi-Valugerdi M; Griskevicius L; Nilsson C; Remberger M; Aschan J; Concha H; Gaughan U; Hassan M
Article: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2006;27(1):54-61
Pharmacogenetics of cyclophosphamide in patients with hematological malignancies
Xie HJ; Griskevicius L; Ståhle L; Hassan Z; Yasar Ü; Rane A; Broberg U; Kimby E; Hassan M
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2005;75(3):206-211
The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma
Afsharian P; Möllgård L; Hassan Z; Xie HJ; Kimby E; Hassan M
Article: JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. 2005;821(1):75-80
Stability, pKa and plasma protein binding of roscovitine
Vita M; Abdel-Rehim M; Nilsson C; Hassan Z; Skansen P; Wan H; Meurling L; Hassan M
Article: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2005;25(1):91-103
Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat
Vita M; Abdel-Rehim M; Olofsson S; Hassan Z; Meurling L; Sidén Å; Sidén M; Pettersson T; Hassan M
Article: ANALYTICA CHIMICA ACTA. 2005;539(1-2):35-39
Microextraction in packed syringe/liquid chromatography/electrospray tandem mass spectrometry for quantification of olomoucine in human plasma samples
Abdel-Rehim M; Skansen P; Vita M; Hassan Z; Blomberg L; Hassan M
Article: EXPERIMENTAL HEMATOLOGY. 2005;33(3):380-387
Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice
Nilsson C; Forsman J; Hassan Z; Abedi-Valugerdi M; O'Connor C; Concha H; Jansson M; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2003;32(4):349-354
N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation
Sjöö F; Aschan J; Barkholt L; Hassan Z; Ringdén O; Hassan M
Article: THERAPEUTIC DRUG MONITORING. 2003;25(3):400-406
On-line derivatization utilizing solid-phase microextraction (SPME) for determination of busulphan in plasma using gas chromatography-mass spectrometry (GC-MS)
Abdel-Rehim M; Hassan Z; Blomberg L; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2002;30(12):833-841
A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation:: 500 mg/m² as a optimal total dose for conditioning
Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
Article: BONE MARROW TRANSPLANTATION. 2002;30(3):141-147
The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo
Hassan Z; Hellström-Lindberg E; Alsadi S; Edgren M; Hägglund H; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2001;28(7):657-664
Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients
Sandström M; Karlsson MO; Ljungman P; Hassan Z; Jonsson EN; Nilsson C; Ringden O; Öberg G; Bekassy A; Hassan M
Article: LEUKEMIA. 2001;15(8):1240-1247
The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro
Hassan Z; Hassan M; Hellström-Lindberg E
Article: BONE MARROW TRANSPLANTATION. 2001;27(5):479-485
Pharmacokinetics of liposomal busulphan in man
Hassan Z; Ljungman P; Ringdén O; Winiarski J; Nilsson C; Aschan J; Whitley HR; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2000;25(9):915-924
The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite:: time interval influence on therapeutic efficacy and therapy-related toxicity
Hassan M; Ljungman P; Ringdén O; Hassan Z; Öberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
Article: EXPERIMENTAL HEMATOLOGY. 1999;27(8):1322-1329
Two pathways of apoptosis induced with all-trans retinoic acid and etoposide in the myeloid cell line P39
Hassan Z; Fadeel B; Zhivotovsky B; Hellström-Lindberg E
Article: LEUKEMIA. 1999;13(5):719-728
Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells
Fadeel B; Hassan Z; Hellström-Lindberg E; Henter JI; Orrenius S; Zhivotovsky B
Article: BONE MARROW TRANSPLANTATION. 1998;22(9):913-918
Liposomal busulphan: bioavailability and effect on bone marrow in mice
Hassan Z; Nilsson C; Hassan M
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 1998;42(6):471-478
Pharmacokinetics and distribution of liposomal busulfan in the rat:: a new formulation for intravenous administration
Hassan M; Hassan Z; Nilsson C; Rehim MA; Kumlien S; Elfsson B; Kållberg N
Article: BONE MARROW TRANSPLANTATION. 1996;18(5):843-850
Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders
Hassan M; Fasth A; Gerritsen B; Haraldsson A; Syruckova Z; vandenBerg H; Sandstrom M; Karlsson M; Kumlien S; Vossen J
Article: PEDIATRIC HEMATOLOGY AND ONCOLOGY. 1996;13(2):143-150
Infection-associated hemophagocytic syndrome complicated by infectious lymphoproliferation: A case report
Syruckova Z; Stary J; Sedlacek P; Smisek P; Vavrinec J; Komrska V; Roubalova K; Vandasova J; Sintakova B; Houskova J; Hassan M
Visa fler

Alla övriga publikationer

Review: PEDIATRIC TRANSPLANTATION. 2011;15(4):348-361
Management of refractory hemorrhagic cystitis following hematopoietic stem cell transplantation in children.
Hassan Z
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2011;17(2):S345
DYNAMICS OF DONOR T CELL ACTIVATION DURING EARLY PHASE OF GRAFT VERSUS HOST DISEASE (GVHD): DONOR ANTIGEN PRESENTING CELLS CAN ACTIVATE ALLOGENEIC T CELLS
Sadeghi B; Al-Hashmi S; Hassan Z; Hassan M
Editorial comment: PEDIATRIC TRANSPLANTATION. 2010;14(6):683-687
Optimal approach to prevent veno-occlusive disease following hematopoietic stem cell transplantation in children.
Hassan Z
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):59
GVHD PROPHYLAXIS USING LOW-DOSE CYCLOSPORINE IS SAFE AND REDUCES THE RISK OF RELAPSE AND DEATH IN LEUKEMIC RECIPIENTS OF HLA-IDENTICAL SIBLING TRANSPLANTS
Olsson R; Remberger M; Mattsson J; Hassan Z; Ringden O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):127
N-ACETYL-L-CYSTEINE PROMOTES T CELL MEDIATED IMMUNITY IN ALLOGENEIC SETTINGS IN VIVO AND IN VITRO
Karlsson H; Nava S; Remberger M; Hassan Z; Hassan M; Ringden O
Meeting abstract: BLOOD. 2006;108(11):97A
Effect of busulphan dose adjustment on regimen-related toxicity.
Hassan Z; Remberger M; Ringden O; Oberg G; Bekassy AN; Hassan M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(2):2
Mesenchymal stem cells for treatment of severe acute graft-versus-host disease
Ringden O; Uzunel M; Rasmusson I; Remberger ME; Sundberg B; Lonnies H; Marschall HU; Dlugosz A; Szakos A; Hassan Z; Omazic B; Aschan J; Barkholt L; Le Blanc K
Thesis / dissertation: 2001
Studies on mechanisms of busulphan cytotoxicity and pharmacokinetics : with special reference to liposomal busulphan
Hassan, Zuzana

Anställningar

Anknuten till Undervisning/Handledning, Laboratoriemedicin, Karolinska Institutet, 2022-2025

Examina och utbildning

Docent, tumörbiologi, Karolinska institutet, 2009
MEDICINE DOKTORSEXAMEN, Institutionen för medicin, Huddinge, Karolinska Institutet, 2001

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI